Aminoglycosides

Antibiotic Discovery and Development

Volumn 9781461414001, Issue , 2012, Pages 229-269

  Armstrong, Eliana S ^a   Kostrub, Corwin F ^a   Cass, Robert T ^a   Moser, Heinz E ^a   Serio, Alisa W ^a   Miller, George H ^a  

^a Achaogen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904802451     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1400-1_7     Document Type: Chapter

References (214)

1. American Thoracic Society (2005) Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416
2. Bruss J, Brooks C, Havrilla N, Cass R, Borin M (2009) Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in human subjects. 49th ICAAC, San Francisco. Presentation F1-1223c
3. Magnet S, Blanchard JS (2005) Molecular insights into aminoglycoside action and resistance. Chem Rev 105:477-497
4. Fourmy D, Recht MI, Blanchard SC, Puglisi JD (1996) Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274:1367-1371
5. Carter AP, Clemons WM, Broderson DE, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V (2000) Functional insights from the structure if 30S ribosomal subunit and its interactions with antibiotics. Nature 407:340-348
6. Ogle JM, Brodersen DE, Clemons WM Jr, Tarry MJ, Carter AP, Ramakrishnan V (2001) Recognition of cognate transfer RNA by the 30S ribosomal subunit. Science 292:897-902
7. Bundtzen RW, Gerber AU, Cohn DL, Craig WA (1981) Postantibiotic suppression of bacterial growth. Rev Infect Dis 3(1):28-37
8. Craig WA (1993) Post-antibiotic effects in experimental infection models: relationship to invitro phenomena and to treatment of infections in man. J Antimicrob Chemother 31(Suppl D):149-158
9. Daikos GL, Jackson GG, Lolans VT, Livermore DM (1990) Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 162(2):414-420
10. Hocquet D, Vogne C, El Garch F, Vejux A, Gotoh N, Lee A, Lomovskaya O, Plésiat P (2003) MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 47(4):1371-1375
11. Tenover FC, Elvrum PM (1988) Detection of two different kanamycin resistance genes in naturally occurring isolates of Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother 32(8):1170-1173
12. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC (2006) Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12:83-88
13. Wright GD (1999) Aminoglycoside-modifying enzymes. Curr Opin Microbiol 2(5): 499-503
14. Jana S, Deb JK (2006) Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol 70:140-150
15. Doi Y, Arakawa Y (2007) 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 45(1):88-94
16. Sakon J, Liao HH, Kanilula AM, Benning MM, Rayment I, Holden HM (1993) Molecular structure of kanamycin nucleotidyltransferase determined to 3.0-A resolution. Biochemistry 32:11977-11984
17. Hon WC, McKay GA, Thompson PR, Sweet RM, Yang DS, Wright GD, Berghuis AM (1997) Strucure of an enzyme required for aminoglycoside resistance reveals homology to eukaryotic protein kinases. Cell 89:887-895
18. Wolf E, Vassilev A, Makino Y, Sali A, Nakatani Y, Burley S (1998) Crystal structure of a GCN5-related N-acetyltransferase: Serratia marcesens aminoglycoside 3-N-acetyltransferase. Cell 94:439-449
19. Radika K, Northrup DB (1984) Correlation of antibiotic resistance with Vmax/Km ratrio of enzymatic modification of aminoglycosides by kanamycin acetyltransferase. Antimicrob Agents Chemother 25:479-482
20. Gates CA, Northrop DB (1988) Alternative substrate and inhibition kinetics of aminoglycoside nucleotidyltransferase 2"-I in support of a Theorell-Chance kinetic mechanism. Biochemistry 27:3826-3833
21. Draker KA, Northrop DB, Wright GD (2003) Kinetic mechanism of the GCN5-related chromosomal aminoglycoside acetyltransferase AAC(6')-Ii from Enterococcus: evidence of dimer subunit cooperativity. Biochemistry 42(21):6565-6574
22. McKay GA, Wright GD (1996) Catalytic mechanism of enterococcal kanamycin kinase (APH(3')-IIIa): viscosity, thio and solvent isotpe effects support a Theorell-Chance mechanism. Biochemistry 35:8680-8685
23. Boehr DD, Daigle DM, Wright GD (2004) Domain-domain interactions in the aminoglycoside antibiotic resistance enzyme AAC(6')-APH(2"). Biochemistry 43:9846-9855
24. Norris AL, Serpersu EH (2009) NMR-detected hydrogen-deuterium exchange reveals differential dynamics of antibiotic- and nucleotide-bound aminoglycoside phosphotransferase 3'-IIIa. J Am Chem Soc 131:8587-8594
25. Wright E, Serpersu EH (2006) Molecular determinants of affinity for aminoglycoside binding to the aminoglycoside nucleotidyltransferase 2"-Ia. Biochemistry 45:10243-10250
26. Owston MA, Serpersu EH (2002) Cloning, overexpression and purification of aminoglycoside antibiotic 3-IIIb acetyltransferase-IIIb: conformational studies with bound substrates. Biochemistry 41:10764-10770
27. Serpersu EH, Ozen C, Wright E (2006) Thermodynamic studies of aminoglycoside antibiotic interactions. Turkish J Biochem 31:79-85
28. Phillips I, Shannon K (1986) Prevalence and mechanisms of aminoglycoside resistance. A ten year study. Am J Med 80:48-55
29. Hare RS, Miller GH, Sabatelli FJ, Weiss WJ, Shlaes DM (1985) Aminoglycoside usage and enzymatic mechanism of resistance. 25th ICAAC, Washington, DC. Abstract 416
30. Hare RS, Shaw KJ, Sabatelli FJ et al (1989) Survey of aminoglycoside resistance in 29 USA hospitals. 29th ICAAC, Washington, DC. Abstract # 675
31. Dornbusch K, Miller GH, Shaw KJ, ESGAR Study Group (1990) Resistance to aminoglycoside antiobiotics in Gram-negative bacilli and staphylococci isolated from blood. Report from a European Collaborative Study. J Antimicrob Chemother 26:131-144
32. The Belgian Aminoglycoside Resistance Study Group, Glupczynski Y, Miller GH, Hare RS, Shaw KJ (1996) Changes in aminoglycoside resistance mechanisms in Belgium over 15 years. 36th ICAAC, Washington, DC. Abstract #C124
33. Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, Shimizu K, Shaw KJ (1997) The most frequent aminoglycoside resistance mechanisms- changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 24(Suppl 1):S46-S62
34. Shaw KJ, Rather PN, Hare RS, Miller GH (1993) Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57(1):138-163
35. Armstrong ES, Biedenbach DJ, Jones RN, Miller GH (2009) Surveying aminoglycosideresistance mechanisms: a tool for the development of neoglycosides. 19th ECCMID, Helsinki. Poster P643
36. Poole K (2005) Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49(2):479-487
37. Marchand I, Damier-Piolle L, Courvalin P, Lambert T (2004) Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 48(9):3298-3304
38. Schatz A, Bugie E, Waksman SA (1944) Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exp Biol Med 55:66
39. Hooper IR (1982) In: Umezawa H, Hooper IR (eds) Aminoglycoside antibiotics. Springer, Berlin
40. Price KE, Godfrey JC, Kawaguchi H (1974) In: Perlman D (ed) Structure-activity relationships among the semisynthetic antibiotics. New York, Academic
41. Waksman SA (1953) Streptomycin: background, isolation, properties, and utilization. Science 118:259-266
42. Harris HW, McClement JH (1977) Pulmonary Tuberculosis. In: Hoeprich PD (ed) Infectious diseases. Harper & Row, Hagerstown
43. Garrod LP, O'Grady F (1968) Antibiotic chemotherapy. Livingstone, Edinburgh
44. Waksman SA, Lechavalier HA (1949) Neomycin, a new antibiotic active against streptomycin- resistant bacteria, including tuberculosis organisms. Science 109:305-307
45. Umezawa H, Okanishi M, Kondo S, Hamana K, Maeda K, Mitsuhashi S (1967) Phosphorylative inactivation of aminoglycoside antibiotics by Escherichia coli carrying R factor. Science 157:1559-1561
46. Brezezinska M, Davies J (1973) Two enzymes which phosphorylate neomycin and kanamycin in Escherichia coli strains carrying R factors. Antimicrob Agents Chemother 3:266-269
47. Coffey GL, Anderson LE, Fisher MW, Galbraith MM, Hillegas AB, Kohberger DL, Thompson PE, Weston KS, Ehrlich JJ (1959) Biological studies of paromomycin. Antibiot Chemother 9:730-738
48. Umezawa H, Ueda M, Maeda K, Yagashita K, Kondo S, Okani Y, Utahara R, Osato Y, Nitta K, Takeuchi TJ (1957) Production and isolation of a new antibiotic, kanamycin. Antibiot Ser A 10:181
49. Umezawa H, Okanishi M, Utahara R, Maeda K, Kondo S (1967) Isolation and structure of kanamycin inactivated by a cell-free system of kanamycin-resistant E. coli. J Antibiot (Tokyo) A20:136-141
50. Weinstein MJ, Leudemann GM, Oden EM, Wagman GH, Rosselet JP, Marquez JA, Coniglio CT, Charney W, Herzog HL, Black JJ (1963) Gentamicin, a new antibiotic complex from Micromonospora. J Med Chem 6:463-464
51. Wagman GH, Weinstein MJ (1980) Antibiotic from Micromonospora. Annu Rev Microbiol 34:537-557
52. Weinstein MJ (2004) Micromonospora antibiotic discovery at Schering-Plough (1961-1973): a personal reminiscence. SIM News 54:56-66
53. Stark WM, Hoehn MM, Knox NG (1968) Nebramycin, a new broad-spectrum antibiotic complex. I. Detection and biosynthesis. Antimicrob Agents Chemother 7:314-323
54. Weinstein MJ, Testa RT, Wagman GH, Oden EM, Waitz JA (1970) Antibiotic 6640, a new Micromonospora-produced aminoglycoside antibiotic. J Antibiot (Tokyo) 23:551-554
55. Weinstein MJ, Wagman GH, Marquez JA, Testa RT, Waitz JA (1975) Verdamicin, a new broad spectrum aminoglycoside antibiotic. Antimicrob Agents Chemother 7:246-249
56. Oda T, Mori T, Ito H, Kunieda T, Munakata K (1971) Studies on new antibiotic lividomycins. I. Taxonomic studies on the lividomycin-producing strain Streptomyces lividus nov. sp. J Antibiot (Tokyo) 24:333-338
57. Shomura T, Ezaki N, Tsuruoka T, Niwa T, Akita E, Nida TJ (1970) Studies on antibiotic SF-733, a new antibiotic. I. Taxonomy, isolation and characterization. J Antibiot (Tokyo) 23:155-161
58. Benveniste R, Davies J (1971) R-factor mediated gentamicin resistance: a new enzyme which modifies aminoglycoside antibiotics. FEBS Lett 14:293-296
59. Brzezinska M, Benveniste R, Davies J, Daniels PJ, Weinstein J (1972) Gentamicin resistance in strains of Pseudomonas aeruginosa mediated by enzymatic N-acetylation of the deoxystreptamine moiety. Biochemistry 11:761-765
60. Benveniste R, Davies J (1973) Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria. Proc Natl Acad Sci USA 70:2276-2280
61. Dion HW, Woo PW, Wilmer NE, Kern DL, Onaga J, Fusari SA (1972) Butirosin, a new aminoglycosidic antibiotic complex: isolation and characterization. Antimicrob Agents Chemother 2:84-88
62. Sugawara S, Inaba S, Madate M, Saeki H, Ohashi Y, Shimada Y, Oki E (1973) Jap Antibiot Res 187th meeting paper #2
63. Hachler H, Santam P, Kayser FH (1996) Sequence and characterization of a novel chromosomal aminoglycoside phosphotransferase gene, aph(3')-IIB, in Pseudomonas aeruginosa. Antimicrob Agents Chemother 40:1254-1256
64. Mann RL, Bromer WW (1958) The isolation of a second antibiotic from Streptomyces hygroscopicus. J Am Chem Soc 80:2714
65. Mason DJ, Dietz A, Smith R (1961) Actinospectacin, a new antibiotic. I. Discovery and biological properties. Antibiot Chemother 11:118-122
66. Nara T, Yamamoto M, Kawamoto I, Takayama K, Okachi R, Takasawa S, Sato T, Sato S (1977) Fortimicins A and B, new aminoglycoside antibiotics. I. Producing organism, fermentation and biological properties of fortimicins. J Antibiot (Tokyo) 30(7):533-540
67. Wagman GH, Testa RT, Marquez JA, Weinstein MJ (1974) Antibiotic G-418, a new Micromonospora-produced aminoglycoside with activity against protozoa and helminths: fermentation, isolation, and preliminary characterization. Antimicrob Agents Chemother 2:144-149
68. Salauze D, Otal R, Gomez-Lus R, Davies J (1990) Aminoglycoside acetyltransferase 3-IV (aacC4) and hygromycin B 4-I phosphotransferase (hphB) in bacteria isolated from human and animal sources. Antimicrob Agents Chemother 34:1915-1920
69. Peck RL, Hoffhine CE, Folkers K (1946) Streptomyces antibiotics. IX. Dihydrostreptomycin. J Am Chem Soc 68:1390-1391
70. Waksman SA, Lechevalier HA (1962) Chapter 3 in "The Actinomycetes". Williams & Wilkins, Baltimore
71. Price KE, Godfrey JC, Kawaguchi H (1977) In: Perlman D (ed) Effect of structural modifications on the biological properties of aminoglycoside antibiotics containing 2- deoxystreptamine. Structure-activity relationships among the semisynthetic antibiotics. Academic, New York/San Francisco/London
72. Reden J, Dürckheimer W (1979) Aminoglycoside antibiotics: chemisry, biochemistry, structure- activity relationship. Top Curr Chem 83:105-170
73. Daniels PJ, Cooper AB, McCombie SW, Nagabhushan TL, Rane DF, Wright JJ (1979) Some recent advances in the chemistry of antibiotics of the gentamicin series. Jpn J Antibiot 32:S195-S204
74. Umezawa S, Tsuchiya T (1982) Total synthesis and chemical modification of the aminoglycoside antibiotics. In: Umezawa H, Hooper IR (eds) Aminoglycoside antibiotics. Springer, Berlin/Heidelberg/New York
75. Nagabhushan TL, Miller GH, Weinstein MJ (1982) Structure-activity relationships in aminoglycoside- aminocyclitol antibiotics. In: Whelton A, Neu HC (eds) The aminoglycosides; microbiology, clinical use and toxicology. Marcel Dekker, New York/Basel
76. Wright GD, Berghuis AM, Mobashery S (1998) Aminoglycoside antibiotics: structures, function, and resistance. Adv Exp Med Biol 456:27-69
77. Kirst HA, Allen NE (2006) Aminoglycoside antibiotics. Compr Med Chem II 7:629-652
78. Li J, Chang C-WT (2006) Recent developments in the synthesis of novel aminoglycoside antibiotics. Anti-Infective Agent Med Chem 5:255-271
79. Silva JG, Carvalho I (2007) New insights into aminoglycoside antibiotics and derivatives. Curr Med Chem 14:1101-1119
80. Van Delftfl(2008) Selective N-derivatization of aminoglycosides en route to new antibiotics and antivirals. In: Ricci A (ed) Amino group chemistry. Wiley-VCH, Weinheim
81. Umezawa S, Jikihara T, Tsuchiya T, Umezawa H (1972) Syntheses of 3'- and 4'-O-methylneamine. J Antibiot 25:322-324
82. Umezawa S, Tsuchiya T, Jikihara T, Umezawa H (1971) Synthesis of 3',4'-dideoxy-neamine active against kanamycin-resistant Escherichia coli and Pseudomonas aeruginosa. J Antibiot 24:711-712
83. Suami T, Nishiyama S, Ishikawa Y, Katsura S (1977) Chemical modification of neamine. Carbohydr Res 53:239-246
84. Hanessian S, Masse R, Nakagawa T (1978) Aminoglycoside antibiotics: studies directed toward the selective modification of hydroxyl groups: synthesis of 3'-epiparomamine and 3'-epineamine. Canadian J Chem 56:1509-1517
85. Nishiyama S, Ishikawa Y, Yamazaki M, Suami T (1978) Chemical modification of neamine. 5. Preparation of aminodeoxyneamines. Bull Chem Soc Jpn 51:555-558
86. Pfeiffer FR, Schmidt SJ, Kinzig CM, Hoover JRE, Weisbach JA (1979) Aminoglycosides, part II. 3' And 4'-axial and equatorial amino and hydroxy derivatives of neamine. Carbohydr Res 72:119-137
87. Umezawa S, Ikeda D, Tsuchiya T, Umezawa H (1973) Synthesis of 1-N-(s)-4-amino-2- hydroxybutyryl)-3',4'-dideoxyneamine. J Antibiot 26:304-306
88. Umezawa H, Umezawa S, Tsuchiya T, Okazaki Y (1971) 3',4'-Dideoxykanamycin B active against kanamycin-resistant Escherichia coli and Pseudomonas aeruginosa. J Antibiot 24:485-487
89. Haskell TH, Rodebaugh R, Plessas N, Watson D, Westland RD (1973) The preparation and biological activity of novel amino acid analogs of butirosin. Carbohy Res 28:263-280
90. Tsukiura H, Fujisawa K, Konishi M, Saito K, Numata K, Ishikawa H, Miyaki T, Tomita K, Kawaguchi H (1973) Aminoglycoside antibiotics. III. Bioactive degradation products from butirosins and semisynthesis of butirosin analogs. J Antibiot 26:351-357
91. Kawaguchi H, Naito T, Nakagawa S, Fujisawa K (1972) BB-K8: a new semisynthetic aminoglycoside antibiotic. J Antibiot 25:695-708
92. Luft FC (1978) Netilmicin: a review of toxicity in laboratory animals. J Int Med Res 6:286-299
93. Lerner AM, Reyes MP, Cone LA, Blair DC, Jansen W, Wright GE, Lorber RR (1983) Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1:1123-1125
94. Daniels PJ, Rane DF, McCombie SW, Testa RT, Wright JJ, Nagabhushan TL (1980) Chemical and biological modification of antibiotics of the gentamicin group. In: Rinehart KL, Suami T (eds) Aminocyclitol antibiotics. ACS, Washington DC
95. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HE (2009) Synthesis, structure, and in vitro activity of the neoglycoside ACHN-490. 49th ICAAC, San Francisco. Poster F1-840
96. Biedenbach DJ, Jones RN, Miller GH, Armstrong ES (2009) Ten year trend in aminoglycosideresistance from a worldwide collection of Gram-negative pathogens (1998-2007). 19th ECCMID, Helsinki. Poster P636
97. Macinga DR, Rather PN (1999) The chromosomal 2'-N-acetyltransferase of Providencia stuartii: physiological functions and genetic regulation. Front Biosci 4:D132-D140
98. Waitz JA, Miller GH, Moss E, Chiu PJ (1978) Chemotherapeutic evaluation of 5-Episisomicin (Sch 22591), a new semisynthetic aminoglycoside. Antimicrob Agents Chemother 13(1):41-48
99. Zahar JR, Lortholary O, Martin C, Potel G, Plesiat P, Nordmann P (2009) Addressing the challenge of extended-spectrum beta-lactamases. Curr Opin Investig Drugs 10(2):172-180
100. Livermore DM (2009) Beta-lactamases - The threat renews. Curr Protein Pept Sci 10(5): 397-400
101. Landman D, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M, Quale J (2007) Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother 60(1):78-82
102. Walsh TR, Toleman MA, Poirel L, Nordmann P (2005) Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 18(2):306-325
103. Centers for Disease Control and Prevention (CDC) (2009) Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 58(10):256-260
104. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP, Colombian Nosocomial Resistance Study Group (2007) First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother 51(4):1553-1555
105. Robledo IE, Aquino EE, Santé MI, Santana JL, Otero DM, León CF, Vázquez GJ (2010) Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob Agents Chemother 54(3): 1354-1357
106. Jones RN, Armstrong ES, Aggen JB, Biedenbach DJ, Miller GH (2009) Antimicrobial activity of ACHN-490, a neoglycoside, tested against a contemporary collection of clinical isolates including problematic antimicrobial-resistant phenotypes. 49th ICAAC, San Francisco. Poster F1-846a
107. Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, Bonomo RA (2009) ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 53(10):4504-4507
108. Georgescu C, Martin DA, Bratu S, Quale J, Landman D (2009) Activity of ACHN-490, a novel neoglycoside antibiotic, against contemporary Gram-negative clinical isolates from Brooklyn, NY Hospitals. 49th ICAAC, San Francisco. Poster F1-842
109. Zurenko G, Stapert D, Knechtel M, Nichols N, Shinabarger D, Armstrong ES, Aggen JB, Feeney LA, Kubo A, Matias RD, Miller GH (2009) The bactericidal activity of the neoglycoside ACHN-490against aminoglycoside-resistant bacteria. 49th ICAAC, San Francisco. Poster F1-841
110. Lin G, Ednie LM, Appelbaum PC (2010) Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay. Antimicrob Agents Chemother, Epub ahead of print
111. Chambers HF, Sande MA (1996) Antimicrobial agents: the aminoglycosides. In: Hardman JG, Limbird LE (eds) Goodman and Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York
112. Parfitt K (ed) (1999) Martindale: the complete drug reference, 32nd edn. Pharmaceutical Press, London, pp 212-215
113. Adelman M, Evans E, Schentag JJ (1982) Two-compartment comparison of gentamicin and tobramycin in normal volunteers. Antimicrob Agents Chemother 22(5):800-804
114. Edwards CQ, Smith CR, Baughman KL, Rogers JF, Lietman PS (1976) Concentrations of gentamicin and amikacin in human kidneys. Antimicrob Agents Chemother 9(6):925-927
115. Frimodt-Moller N (2002) Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infections. Int J Antimicrob Agents 19:546-553
116. Bergeron MG, Marois Y (1986) Benefit from high intrarenal levels of gentamicin in the treatment of E. coli pyelonephritis. Kidney Int 30:481-487
117. Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G (2005) Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 128:545-552
118. Boselli E, Breilh D, Djabarouti S, Guillaume C, Rimmelé T, Gordien JB, Xuereb F, Saux MC, Allaouchiche B (2007) Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med 33(9):1519-1523
119. Valcke YJ, Vogelaers DP, Colardyn FA, Pauwels RA (1992) Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 101(4):1028-1032
120. Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, Mattie H, Craig WA Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models J Infect Dis 1989, 159, 2, 281-292.
121. Cass RT, McKinnell JV, Xie B, Karr DE, Schmidt DE Jr (2009) Pharmacokinetics of the novel neoglycoside ACHN-490 in mouse, rat, and dog. 49th ICAAC, San Francisco. Poster F1-846
122. Bodey GP, Chang HY, Rodriguez V, Stewart D (1975) Feasibility of administering aminoglycoside antibiotics by continuous intravenous infusion. Antimicrob Agents Chemother 8(3): 328-333
123. Chuck SK, Raber SR, Rodvold KA, Areff D (2000) National survey of extended-interval aminoglycoside dosing. Clin Infect Dis 30:433-439
124. Fantin B, Leggett J, Ebert S, Craig WA (1991) Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother 35(7):1413-1422
125. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A (2007) Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45: 753-760
126. Craig WA, Redington JA, Ebert SC (1991) Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infection. J Antimicrob Ther 27:29-40
127. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL (1999) Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43:1549-1555
128. Moore RD, Smith CR, Lietman PS (1984) The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 149(3):443-448
129. Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155(1):93-99
130. Moore RD, Smith CR, Lietman PS (1984) Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 77:657-662
131. Kashuba ADM, Bertino JS, Nafziger AN (1998) Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother 42(7):1842-1844
132. Kashuba ADM, Nafziger AN, Drusano GL, Bertino JS (1999) Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 43(3):623-629
133. Zelenitsky SA, Harding GKM, Sun S, Ubhi K, Ariano RE (2003) Treatment and outcome of Pseudomonas aeruginosa bacteremia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 52:668-674
134. Bastone EB, Li SC, Ioannides-Demos LL, Spicer WJ, McLean AJ (1993) Kill kinetics and regrowth patterns of Eschenichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing. Antimicrob Agents Chemother 37(4):914-917
135. Kozak AJ, Gerdin DN, Peterson LR, Hall WH (1977) Gentamicin intravenous infusion rate: effect on interstitial fluid concentration. Antimicrob Agents Chemother 12(5):606-608
136. Snavely SR, Hodges GR (1984) The neurotoxicity of antibacterial agents. Ann Intern Med 101:92-104
137. Rutten JM, Booij LH, Rutten CL, Crul JF (1980) The comparative neuromuscular blocking effects of some aminoglycoside antibiotics. Acta Anaesthesiol Belg 31(4):293-306
138. Liu M, Kato M, Hashimoto Y (2001) Neuromuscular blocking effects of the aminoglycoside antibiotics arbekacin, astromicin, isepamicin and netilmicin on the diaphragm and limb muscles in the rabbit. Pharmacology 63:142-146
139. Komiya I, Murata S, Umemura K, Tomono N, Kikai S, Fujita M (1981) Acute toxicity and pharmacokinetics of dibekacin mice. J Pharmacobiodyn 4(5):356-361
140. Hock R, Anderson RJ (1995) Prevention of drug-induced nephrotoxicityin the intensive care unit. J Crit Care 10(1):33-43
141. Humes HD, Weiner ND, Schacht J (1982) The biochemical pathology of aminoglycosideinduced nephro and ototoxicity. In: Fillastre JP (ed) Nephrotoxicity and ototoxicity of drugs. INSERM, Paris
142. Bertino JS, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN (1993) Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 167(1):173-179
143. Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM (1990) Risk of nephrotoxicity with combination Vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 10(6): 378-382
144. Ali MZ, Goetz MB (1997) A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24:796-809
145. Bailey TC, Little JR, Littenberg B (1997) A meta-analysis of extended-interval dosing vs. multiple dosing of aminoglycosides. Clin Infect Dis 24:786-795
146. Beaucaire G (2000) Does once-daily dosing prevent nephrotoxicity in all aminoglycosides equally? Clin Microbiol Infect 6(7):357-362
147. Hatala R, Dinh T, Cook DJ (1996) Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 124:717-725
148. Hatala R, Dinh TT, Cook DJ (1997) Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 24:810-815
149. Koo J, Tight R, RajkumarV HZ (1996) Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Am J Med 101:177-183
150. Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA (1979) The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 140(4):576-580
151. Bennett WM, Plamp CE, Parker RA, Gilbert DN, Houghton DC, Porter GA (1979) Renal transport of organic acids and bases in aminoglycoside nephrotoxicity. Antimicrob Agents Chemother 16(2):231-233
152. Kostrub CF, Diokno R, Aggen JB, Miller GH, Judice JK, Tulkens P (2009) Quantitative comparison of aminoglycoside nephrotoxicity in rats for effective screening and evaluation of new derivatives, and dosing rationales that minimise toxicity. 19th ECCMID Helsinki. Poster P1979
153. Gilbert DN, Plamp CE, Starr P, Bennett WM, Houghton DC (1978) Comparative nephrotoxicity of gentamicin and tobramycin. Antimicrob Agents Chemother 13(1):34-40
154. Houghton DC, Plamp CE 3rd, DeFehr JM, Bennett WM, Porter G, Gilbert D (1978) Gentamicin and tobramycin nephrotoxicity. A morphologic and functional comparison in the rat. Am J Pathol 193(1):137-152
155. Brion N, Barge J, Godefroy I, Dromer F, Dubois C, Contrepois A, Carbon C (1984) Gentamicin, netilmicin, dibekacin, and amikacin nephrotoxicity and its relationship to tubular reabsorption in rabbits. Antimicrob Agents Chemother 25(2):168-172
156. Brier ME, Mayer PR, Brier RA, Visscher D, Luft FC, Aronoff GR (1985) Relationship between rat renal accumulation of gentamicin, tobramycin, and netilmicin and their nephrotoxicities. Antimicrob Agents Chemother 27(5):812-816
157. Luft FC, Patel V, Yum MN, Kleit SA (1976) Nephrotoxicity of cephalosporin-gentamicin combinations in rats. Antimicrob Agents Chemother 9(5):831-839
158. Adelman RD, Conzelman G, Spangler W, Ishizaki G (1979) Comparative nephrotoxicity of gentamicin and netilmicin: functional and morphological correlations with urinary enzyme activities. Curr Probl Clin Biochem 9:166-182
159. Waikar SS, Bonventre JV (2008) Biomarkers for the diagnosis of acute kidney injury. Nephron Clin Pract 109(4):192-197
160. Stone HH, Kolb LD, Geheber CE, Dawkins EJ (1976) Use of aminoglycosides in surgical infections. Ann Surg 183:660-666
161. Maki DG, Craig WA, Agger WA (1979) A comparative clinical trial of sisomicin and gentamicin in major Gram negative infections. Infection 7(suppl 3):S298-S300
162. Schieker KR, Hofmann HF (1981) Prospective double-blind controlled clinical study of sisomicin versus tobramycin. Pharmatherapeutica 2(8):499-503
163. Kahlmeter G, Dahlager JI (1984) Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemoth 13(Suppl A):9-22
164. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D (2004) Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 38:1538-1544
165. Craig WA (1995) Once-daily versus multiple-daily dosing of aminoglycosides. J Chemother 7(Suppl 2):47-52
166. Yoshida M, Morita R, Lefor AT, Nabeshima T (2007) Implementation and evaluation of a once-daily amikacin dosing protocol in a long-term care facility. Int J Antimicrob Agents 29:112-116
167. Moestrup SK, Cui S, Vorum H, Bregengard C, Bjorn SE, Norris K, Gliemann J, Christensen EI (1995) Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 96(3):1404-1413
168. Schacht J (1979) Isolation of an aminoglycoside receptor from guinea pig inner ear tissues and kidney. Arch Otorhinolaryngol 224:129-134
169. Schmitz C, Hilpert J, Jacobsen C, Boensch C, Christensen EI, Luft FC, Willnow TE (2002) Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 277:618-622
170. Giuliano RA, Verpooten GA, Verbist L, Weeden R, DeBroe ME (1986) In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 236:470-475
171. Tran Ba Huy P, Bernard P, Schacht J (1986) Kinetics of gentamicin uptake and release in the rat: comparison of inner ear tissues and fluids with other organs. J Clin Invest 77: 1492-1500
172. Giuliano RA, Verpooten GA, De Broe ME (1986) The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. Am J Kidney Dis 8(5):297-303
173. Lambrecht P, Matsumoto K, Leal T, Wallemacq P, Donnez J, Tulkens PM (1990) Evaluation of the safety of isepamicin in animal models and in humans. In: Proceedings of the 9th international symposium on future trends in chemotherapy, Geneva
174. Rougier F, Claude D, Maurin M, Sedoglavic A, Ducher M, Corvaisier S, Jelliffe R, Maire P (2003) Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother 47(3):1010-1016
175. Frame PT, Phair JP, Watanakunakorn C, Bannister TWP (1977) Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis 135:952-956
176. Tran Ba Huy P, Deffrennes D (1988) Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta Otolaryngol 105:511-515
177. De Broe ME, Giuliano RA, Verpooten GA (1986) Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. Am J Med 80(6B):115-118
178. De Broe ME, Verbist L, Verpooten GA (1991) Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 27(Suppl C):41-47
179. Mingeot-Leclercq MP, Tulkens PM (1999) Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 43(5):1003-1012
180. Vandewalle A, Farman N, Morin JP, Fillastre JP, Hatt PY, Bonvalet JP (1981) Gentamicin incorporation along the nephron: autoradiographic study on isolated tubules. Kidney Int 19(4):529-539
181. Begg EJ, Barclay ML (1995) Aminoglycosides-50 years on. Br J Clin Pharm 39:597-603
182. Kosek JC, Mazze RI, Cousins MJ (1974) Nephrotoxicity of gentamicin. Lab Invest 30(1):48-57
183. Humes HD (1999) Insights into ototoxicity. Analogies to nephrotoxicity. Ann N Y Acad Sci 28(884):15-18
184. Forge A, Schacht J (2000) Aminoglycoside antibiotics review. Audiol Neurootol 5:3-22
185. Priuska EM, Schaacht J (1995) Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem Pharmacol 50(11):1749-1752
186. Gabev E, Kasianowicz J, Abbott T, McLaughlin S (1989) Binding of neomycin to phosphatidylinositol 4,5-bisphosphate (PIP2). Biochim Biophys Acta 979:105-112
187. Schacht J (1993) Biochemical basis of aminoglycoside ototoxicity. Otolaryngol Clin North Am 26(5):845-856
188. Smith CR, Lipsky JJ, Lietman PS (1979) Relationship between aminoglycoside-induced toxicity and auditory toxicity. Antimicrob Agents Chemother 15(6):780-782
189. Moore RD, Smith CR, Lietman PS (1984) Risk factors for the development of auditory toxicity in patient receiving aminoglycosides. J Infect Dis 149:23-30
190. Fischel-Ghodsian N (2005) Genetic factors in aminoglycoside toxicity. Pharmacogenomics 6(1):27-36
191. Sha SH, Schacht J (1997) Prevention of aminoglycoside-induced hearing loss. Keio J Med 46(3):115-119
192. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R (1995) Experience with once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 39:650-655
193. Black FO, Gianna-Poulin C, Pesznecker SC (2001) Recovery from vestibular ototoxicity. Otol Neurotol 22:662-671
194. Kitasato I, Yokota M, Inouye S, Igarashi M (1990) Comparative ototoxicity of ribostamycin, dactimicin, dibekacin, kanamycin, amikacin, tobramycin, gentamicin, sisomicin and netilmicin in the inner ear of guinea pigs. Chemotherapy 36(2):155-168
195. Brummett RE, Fox KE, Bendrick TW, Himes DL (1978) Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin in the guinea pig. J Antimicrob Chemother 4(Suppl A):73-83
196. Anniko M, Takada A, Schacht J (1982) Comparative ototoxicities of gentamicin and netilmicin in three model systems. Am J Otolaryngol 3:422-433
197. Parravicini L, Arpini A, Bamonte F, Marzanatti M, Ongini E (1982) Comparative ototoxicity of amikacin, gentamicin, netilmicin, and tobramycin in guinea pigs. Toxicol Appl Pharmacol 65:222-230
198. Brummett RE, Fox KE (1989) Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 33(6):797-800
199. Munckhof WJ, Grayson ML, Turnidge JD (1996) A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 37:645-663
200. Agrawal Y, Platz EA, Niparko JK (2008) Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and Nutrition Examination Survey, 1999-2004. Arch Intern Med 168(14):1522-1530
201. Agrawal Y, Carey JP, Della Santina CC, Schubert MC, Minor LB (2009) Disorders of balance and vestibular function in US adults: data from the National Health and Nutrition Examination Survey, 2001-2004. Arch Intern Med 169(10):938-944
202. Zheng G, Bachinsky DR, Stamenkovic I, Strickland DK, Brown D, Andres G, McCluskey RT (1994) Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, Gp330 and LRP/a2MR, and the receptor-associated protein (RAP). J Histochem Cytochem 42:531-542
203. Myrdal SE, Steyger PS (2005) TRPV1 regulators mediate gentamicin penetration of cultured kidney cells. Hear Res 204(1-2):170-182
204. De Groot JC, Meeuwsen F, Ruizendaal WE, Veldman JE (1990) Ultrastructural localization of gentamicin in the cochlea. Hear Res 50(1-2):35-42
205. De Groot JC, Huizing EH, Veldman JE (1991) Early ultrastructural effects of gentamicin cochleotoxicity. Acta Otolaryngol 111(2):273-280
206. Servais H, Jossin Y, Van Bambeke F, Tulkens PM, Mingeot-Leclercq MP (2006) Gentamicin causes apoptosis at low concentrations in renal LLC-PK1 cells subjected to electroporation. Antimicrob Agents Chemother 50:1213-1221
207. Henley CM, Schacht J (1988) Pharmacokinetics of aminoglycoside antibiotics in blood, inner-ear fluids and tissues and their relationship to ototoxicity. Audiology 27(3):137-146
208. Dulon D, Aran JM, Zajic G, Schacht J (1986) Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule. Antimicrob Agents Chemother 30(1): 96-100
209. Aran JM, Chappert C, Dulon D, Erre JP, Aurousseau C (1995) Uptake of amikacin by hair cells of the guinea pig cochlea and vestibule and ototoxicity: comparison with gentamicin. Hear Res 82(2):179-183
210. Ohtani I, Ohtsuki K, Aikawa T, Omata T, Ouchi J, Saito T (1982) Ototoxicity of aminoglycoside antibiotics by rapid intravenous injection. ORL J Otorhinolaryngol Relat Spec 44(3): 156-169
211. Nakashima T, Teranishi M, Hibi T, Kobayashi M, Umemura M (2000) Vestibular and cochlear toxicity of aminoglycosides-a review. Acta Otolaryngol 120:904-911
212. Bamonte F, Dionisotti S, Gamba M, Ongini E, Arpini A, Melone G (1990) Relation of dosing regimen to aminoglycoside ototoxicity: evaluation of auditory damage in the guinea pig. Chemotherapy 36(1):41-50
213. Pettorossi VE, Ferraresi A, Errico P, Draicchio F, Dionisotti S (1990) The impact of different dosing regimens of the aminoglycosides netilmicin and amikacin on vestibulotoxicity in the guinea pig. Eur Arch Otorhinolaryngol 247(5):277-282
214. Takumida M, Nishida I, Nikaido M, Hirakawa K, Harada Y, Bagger-Sjöbäck D (1990) Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin. ORL J Otorhinolaryngol Relat Spec 52(6):341-349